Article
One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.
All News
Article
Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.
Article
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.
Article
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Dr. John Cush
Tweet
Methotrexate - an old trusted friend who deserves better
MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice.
https://t.co/rSHsysJQ46 https://t.co/OKfBiMlqyg
Dr. John Cush
Tweet
Rheumatoid Arthritis, Radiomics and Interstitial Lung Disease
Drs. Antoni Chan and Vincenzo Venerito discuss abstracts OP0127 and POS0855 presented at EULAR 2023 in Milan, Italy.
https://t.co/SuMMrkwfvk https://t.co/hSSPKIW4Os
Dr. John Cush
Tweet
Difficult to treat RA is Actually Difficult to Define
Dr. Janet Pope discusses abstract OP0134 presented at EULAR 2023 in Milan, Italy.
https://t.co/0J9mH9n8jJ https://t.co/JT1hGp2S5w
Dr. John Cush
Tweet
Are T cells the missing link in pre-clinical RA?
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Dr.Najm ( @AurelieRheumo ) shares #EULAR23 presentations on this topic.
https://t.co/qVyDp6Gs2y https://t.co/mqxNLIxShd
Dr. John Cush
Tweet
RA and cancer risk in the biologic era
RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era.
https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly
Dr. John Cush
Tweet
AI in RA: the story grows along the patient pathway
The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA.
https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM
Dr. Antoni Chan
Tweet
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan
Tweet
The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2
Dr. John Cush
Tweet
Better at Predicting RA from MRI: Humans or Computers?
https://t.co/xRVatfiRKS https://t.co/Gwypq8lcdl
Bella Mehta
Tweet
JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
Bella Mehta
Tweet
Abstracts talking about #RA and JAKs and Biologic comparisons
Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below
@RheumNow https://t.co/jl5S4fLq19
Bella Mehta
Tweet
Abatacept in pts at risk of #RA data from clinical trial.
213 pts, 31 centers.
Pts with multiple autoantibodies improved the most with abatacept.
@rheumnow #EULAR2023 https://t.co/c82jx0cAEq
Aurelie Najm
Tweet
Treat early it is also cheaper!
5 yr cost of RA ttmt
€11250 ACPA+ > €3526 ACPA-
bDMARDS users
€44788 ACPA+ > €40896 ACPA-
ACPA- "late" ttmt 46% more expensive
ACPA+ early vs. late = similar costs
@Rheumnow #EULAR23 POS0369 https://t.co/dg9T9fqJDl
Janet Pope
Tweet
In ERA high BMI is associated with high BMI is assoc with failure to get to Low disease activity. From NORD-STAR RCT. Cdn CATCH cohort in #early #Rheumatoid #arthritis also shows I is associated w less remission and less sustained remission #EULAR2023 @RheumNow POS0324 https://t.co/9EXY8Dyz74
Janet Pope
Tweet
Predictive model to predict RA status via AI , to know what goes in to model or predictions may change. Ex use of DMARDs https://t.co/fkcEKfZWl8
Aurelie Najm
Tweet
We would think that targeted therapies would have reduced GC use in RA.
Well, this is not really the case.
Comaprison of GC use in 1999-2008 vs. 2009-2018
52% of patients remain on GC for>3Mo after initiation & 1/3 still continues after 2 years!
@RheumNow #EULAR23 POS0309 https://t.co/dDkUJFlmEm
